USPSTF: Evidence Lacking for Lipid Disorder Screening in Children
Current evidence is inadequate for assessing the balance of benefits and harms of screening in a pediatric population
Diagnosis & Disease Information
Lomitapide Reduces LDL-C in Children With Homozygous Familial Hypercholesterolemia
The APH-19 trial enrolled a total of 46 patients 5 to 17 years of age with HoFH who had a mean LDL-C at baseline of 436 mg/dL.
Statin Use Linked to Reduced Risk for Intracerebral Hemorrhage
Risk reduced for lobar and nonlobar intracerebral hemorrhage; greater reductions seen with prolonged use ≥5 years
Clinician Nudge Ups Initiation of Statin Prescribing in Primary Care
Clinician nudge alone or in combination with a patient nudge increases initiation of statin prescribing versus usual care
Evinacumab Under Review for Pediatric Homozygous Familial Hypercholesterolemia
Evinacumab is a fully-human monoclonal antibody that binds to and blocks the function of angiopoietin-like 3.
Low-Dose Statin Bests Six Commonly Used Cholesterol Health Supplements
The study included adults aged 40 to 75 years with no history of cardiovascular disease, an LDL-C of 70-189 mg/dL, and a 5-20% 10-year risk of ASCVD.
Cardiovascular Benefits of Statins Outweigh Low Risk for Muscle Symptoms
Only one of 15 muscle symptom-related reports by study participants assigned to statins believed to be due to statins
Guidance Developed for Addressing Use of Nonstatin Therapies
Expert consensus decision pathway developed for patients currently taking statins and needing additional treatment
FOURIER-OLE: Long-Term LDL-C Lowering With Evolocumab Safe, Cuts MACE Risk
Findings showed that treatment with evolocumab resulted in clinically significant and sustained reduction in LDL-C levels.
USPSTF Issues Final Recommendations on Statin Use for Primary Prevention of CVD
These recommendations apply only to individuals without a history of CVD and who are not already taking statins.
